Underneath the broader market volatility, I'm told that specialized sectors from nuclear energy to biopharma are seeing their most significant overhaul since early last year. According to people familiar with the matter, capital flows and technological breakthroughs are quietly reshaping these non-mainstream equities. Here is what I am hearing about their latest moves.

Ur-Energy (URG.US) & Lightbridge (LTBR.US)

Uranium and nuclear technology players are gaining serious momentum. Ur-Energy is aggressively advancing its in-situ recovery projects. I'm told the company received crucial regulatory authorization in mid-2026 to transport and process uranium-bearing materials from its Shirley Basin facility. Meanwhile, Lightbridge recently hit a major developmental milestone for its extruded solid fuel technology at the Idaho National Laboratory. The stock's recent inclusion in a global uranium index has helped it outperform many peers this year.

Summit Therapeutics (SMMT.US)

The oncology drug developer's pipeline for its bispecific antibody is advancing faster than expected. According to sources, Summit initiated a Phase II/III study for first-line bladder cancer in August 2026 to evaluate the potential of ivonescimab. Although the company posted substantial net losses in Q4 2025, its recent move to divest a legacy antibiotic asset to an AI-native biopharma firm signals a complete, laser-focused pivot toward oncology.

Diamondback Energy (FANG.US)

The traditional energy heavyweight continues to shatter production records. I've learned that Diamondback's total production surpassed the one-million-barrels-of-oil-equivalent-per-day mark for the first time in Q2 2026, reaching 1.018 million BOE/d. More significantly, the board made a massive move in late July by doubling its share repurchase authorization to USD 16 billion. With Q2 net income hitting USD 1.88 billion, up massively year-over-year, the stock has been kept on a steady upward trajectory recently.

Atomera (ATOM.US)

This semiconductor materials firm is looking for new growth curves in the RF application space. Atomera showcased a novel gallium-nitride-on-silicon approach for RF devices in Q2 2026, which boasts significantly lower harmonic distortion than control devices. While the company only generated USD 158,000 in quarterly revenue and remains unprofitable, I'm told that interest from major DRAM and flash memory suppliers regarding its GAA technology is growing rapidly.

Also

• AGNC Investment (AGNC.US): The mortgage REIT reported a tangible net book value increase to USD 8.58 per share in Q2 2026, maintaining its steady stream of monthly dividends amid shifting interest rate expectations.
• POMDOCTOR (POM.US): After regaining compliance with Nasdaq's listing requirements, the online healthcare platform is heavily pushing its AI-driven chronic disease management strategy, with audited net revenues climbing to roughly USD 59 million in FY 2025.
• Avantor (AVTR.US): The company posted net sales of roughly USD 1.69 billion for Q2 2026 and is currently co-developing a long-acting HIV prevention product through its NuSil brand, maintaining a stable market position.
• U.S. Gold Corp. (USAU.US): The company is actively advancing exploration at its CK Gold Project in Wyoming, and I'm told new drilling plans are being formulated to test resource expansion potential in the area.
• Ubisoft Entertainment (UBSFY.US): The French video game publisher's interactive entertainment pipeline is facing a market reassessment, and industry watchers are closely eyeing its release cadence later this year.

This article does not constitute investment advice.